Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jennifer Van Eyk, George Scangos


Jennifer Van Eyk has been named the inaugural director of Cedars-Sinai's Advanced Clinical Biosystems Research Institute, Cedars-Sinai said this week. She also will lead basic research at the Cedars-Sinai Barbara Streisand Women's Heart Center.

Van Eyk joins Cedars-Sinai from Johns Hopkins University School of Medicine. A proteomics investigator, she is known for developing lab tests to determine the presence of proteins in blood that could indicate whether a patient has experienced a heart attack or has heart disease. She will remain director of the National Heart Lung and Blood Institute Proteomic Innovation Center on Heart Failure, a contract NHLBI awarded to her group at Johns Hopkins.

Agilent said this week that it has appointed Biogen Idec CEO George Scangos to its board of directors, effective September.

Prior to Biogen, Scangos served as president and CEO of Exelixis, a drug discovery and development company. He was previously president of Bayer Biotechnology.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.